Anthony  L.  McCall Degree(s): MD, PhD Graduate School: Medical College of Wisconsin; Massachusetts Institute of Technology Residency and Fellowship: Boston University Primary Appointment: Professor, Medicine, Endocrinology and Metabolism Research Interests: Brain metabolism, hypoglycemia, diabetes and the nervous system, cardiovascular disease and diabetes, artificial pancreas for type 1 diabetes, inpatient diabetes management. Email Address: alm3j@virginia.edu

Research Description

Brain metabolism, hypoglycemia, diabetes and the nervous system, mathematical analysis of glycemic patterns, glucagon pulsatile secretion and hypoglycemia, genetics of cardiovascular risk and type-2 diabetes mellitus, cardiovascular risk and diabetes therapies.
 
Our work is currently funded by:

NIH R01 HL085224

• Principal Investigator UVA site, “Non-modulation phenotype and Vascular Dysfunction in Diabetes,” 06/2007- 06/2011

• Co-Investigator, Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System -- protocol titled: "Pramlintide Combined with Zone Model Predictive Control Algorithm," 09/2009-08/2012

NIH R01 DK082805

• Co-Principal Investigator, “Pancreatic endocrine network control of glucagon counterregulation,” 04/15/2010-03/31/2014
  

Selected Publications

McCall AL. Insulin therapy and hypoglycemia. Endocrinol Metab Clin North Am. 2012 Mar;41(1):57-87. doi: 10.1016/j.ecl.2012.03.001. Epub 2012 Apr 17. Review. PubMed PMID: 22575407.

Farhy LS, Chan A, Breton MD, Anderson SM, Kovatchev BP, McCall AL. Association of Basal hyperglucagonemia with impaired glucagon counterregulation in type 1 diabetes. Front Physiol. 2012;3:40. doi: 10.3389/fphys.2012.00040. Epub 2012 Feb 28. PubMed PMID: 22403550; PubMed Central PMCID: PMC3288769.

Farhy LS, McCall AL. Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency. Diabetes Obes Metab. 2011 Oct;13 Suppl 1:133-43. doi: 10.1111/j.1463-1326.2011.01455.x. Review. PubMed PMID: 21824267; PubMed Central PMCID: PMC3289058.

McCall AL. What's wrong with too low? Is hypoglycemia a marker or a cause of CVD and mortality risk? Curr Diab Rep. 2011 Apr;11(2):71-4. doi: 10.1007/s11892-010-0174-7. PubMed PMID: 21222055.

Farhy LS, McCall AL. Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action. J Diabetes Sci Technol. 2010 Nov 1;4(6):1345-56. PubMed PMID: 21129329; PubMed Central PMCID: PMC3005044.

McCall AL. Is there a magic diet? Studying the balance of macronutrients needed for best weight loss. Curr Diab Rep. 2010 Jun;10(3):165-9. doi: 10.1007/s11892-010-0105-7. PubMed PMID: 20425577.

Lieb DC, McCall AL. Update on the safety of thiazolidinediones. Curr Diab Rep. 2010 Apr;10(2):116-23. doi: 10.1007/s11892-010-0099-1. Review. PubMed PMID: 20425570.

McCall AL. When is evidence of lack of harm enough? Has the rosiglitazone controversy ended? Curr Diab Rep. 2009 Oct;9(5):325-8. PubMed PMID: 19793499.

McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B. Reduced dailyrisk of glycemic variability: comparison of exenatide with insulin glargine. Diabetes Technol Ther. 2009 Jun;11(6):339-44. doi: 10.1089/dia.2008.0107. PubMed PMID: 19459761; PubMed Central PMCID: PMC2768873.

Farhy LS, McCall AL. System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency. J Diabetes Sci Technol. 2009 Jan;3(1):21-33. PubMed PMID: 20046648; PubMed Central PMCID: PMC2769841.

PubMed Listings for this Faculty Member